Charles River Laboratories (CRL) Tops Q3 EPS by 9c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Price: $332.89 -5.39%
Financial Fact:
Operating income: 58.8M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Operating income: 58.8M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.43, $0.09 better than the analyst estimate of $2.34. Revenue for the quarter came in at $1 billion versus the consensus estimate of $987.43 million.
GUIDANCE:
Charles River Laboratories sees FY2025 EPS of $10.10-$10.30, versus the consensus of $10.19.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Fidelity National Information Services (FIS) to Market Perform
- Avnet (AVT) Tops Q1 EPS by 97c ; Offers Guidance
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
